1
|
Salgado MV, Penko J, Fernandez A, Mejia R. Modelling the impact of plain packaging of tobacco products on cardiovascular disease in Argentina. Tob Control 2023; 32:255-258. [PMID: 34261789 DOI: 10.1136/tobaccocontrol-2021-056651] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 06/19/2021] [Indexed: 11/03/2022]
Abstract
INTRODUCTION Tobacco packaging design is conceived to be attractive. Plain packaging of tobacco products reduces this attractiveness by standardising their shape, size, font and colours. METHODS To evaluate the effect of applying plain packaging to tobacco products on cardiovascular events and mortality in Argentina, we used the Cardiovascular Disease Policy Model-Argentina, a local adaptation of a well-established computer simulation model that projects cardiovascular and mortality events for the population 35-94 years old using local demographic and consumption data, during the period 2015-2024. After a literature review, we estimated that the implementation of plain packaging of tobacco products would result in an absolute decrease in tobacco prevalence of 0.55% (base-case scenario) and performed a sensitivity analysis assuming a higher and lower decrease of 1.01% and 0.095%, respectively. RESULTS Over the 2015-2024 period, the decrease in smoking prevalence associated with plain packaging (0.55%) is projected to avert 1880 myocardial infarctions (MI), 820 strokes and 4320 total deaths in Argentina. The higher estimate of smoking prevalence reduction (1.01%) would translate into 3450 fewer MIs, 1490 fewer strokes and 7920 fewer deaths, while the lower estimate of smoking prevalence reduction (0.095%) would result in 330 fewer MIs, 140 fewer strokes and 750 fewer deaths. CONCLUSIONS The implementation of plain packaging of tobacco products could reduce cardiovascular events in Argentina, even in the absence of other tobacco control measures. Actual health benefits are likely higher than those presented here, since plain packaging may be most impactful by preventing young people from initiating smoking.
Collapse
Affiliation(s)
- M Victoria Salgado
- Área de Salud, Economía y Sociedad, Centro de Estudios de Estado y Sociedad, Ciudad de Buenos Aires, Argentina
- Servicio de Medicina Familiar, Hospital SAMIC El Calafate, El Calafate, Argentina
| | - Joanne Penko
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, USA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
| | - Alicia Fernandez
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, USA
- Department of Medicine, University of California San Francisco, San Francisco, California, USA
| | - Raul Mejia
- Área de Salud, Economía y Sociedad, Centro de Estudios de Estado y Sociedad, Ciudad de Buenos Aires, Argentina
- Programa de Medicina Interna General, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
| |
Collapse
|
2
|
Ríos-Fetchko F, Fernández A, Mejía R, Salgado MV. [Disparities in regional obesity rates in Argentina by socioeconomic status]. Medicina (B Aires) 2023; 83:366-375. [PMID: 37379533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023] Open
Abstract
BACKGROUND Obesity rates in Latin America are increasing overall and among people with low socioeconomic status (SES). Obesity and SES disparities can vary by region-a valuable indicator of local drivers. The objective of this study was to examine regional and SES differences in obesity in Argentina. METHODS We used data from Argentina's 4th National Risk Factors Survey (n = 29226) 2018 and defined obesity as BMI = 30. Low SES was defined as not finished high school or having a household income in the lowest two quintiles. Descriptive analysis stratified by sex compared obesity rates by SES, province, and region. Age-adjusted logistic regression models explored the association between obesity, socioeconomic status, and region. RESULTS Obesity rates varied more by SES among women (39% for low SES vs. 26% for middle/high SES; p < 0.001) than among men (33% low SES vs. 29% middle/ high SES; p = 0.027). The Patagonian region had the highest obesity prevalence for both men (36%) and women (37%). A gender-stratified age-adjusted analysis with region and SES showed that low SES (OR 1.72, 95% CI 1.45, 2.03) and the Patagonian region (OR 1.29, 95% CI 1.02, 1.62) were the only significant predictors for women. CONCLUSIONS SES associated disparities in obesity in Argentina were pronounced for women but not men. Disparities were particularly high in Patagonia. Further research is needed to understand the drivers behind these SES, regional, and gender disparities.
Collapse
Affiliation(s)
| | - Alicia Fernández
- University of California, San Francisco, San Francisco, CA, USA
- Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina
| | - Raúl Mejía
- Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina
- Hospital de Clínicas José de San Martín, Buenos Aires, Argentina
| | - M Victoria Salgado
- Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina. E-mail:
- Unidad de Conocimiento Traslacional Hospitalaria Patagónica, Hospital SAMIC El Calafate, Santa Cruz, Argentina
| |
Collapse
|
3
|
Duarte M, Pelorosso F, Nicolosi LN, Victoria Salgado M, Vetulli H, Aquieri A, Azzato F, Castro M, Coyle J, Davolos I, Criado IF, Gregori R, Mastrodonato P, Rubio MC, Sarquis S, Wahlmann F, Rothlin RP. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine 2021; 37:100962. [PMID: 34189447 PMCID: PMC8225700 DOI: 10.1016/j.eclinm.2021.100962] [Citation(s) in RCA: 84] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 05/09/2021] [Accepted: 05/26/2021] [Indexed: 02/07/2023] Open
Abstract
Background Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 years of age hospitalized with Covid-19 with 4 or fewer days since symptom onset enrolled at a university and a community hospital in Buenos Aires, Argentina. Exclusion criteria included prior intensive care unit (ICU) admission and use of ARBs/angiotensin converting enzyme inhibitors at randomization. Control arm received standard care alone and treatment arm telmisartan 80 mg twice daily for 14 days. Primary outcomes were C-reactive protein (CRP) plasma levels at day 5 and 8 after randomization. Secondary outcomes included time to discharge within 15 days, admission to ICU and death at 15- and 30-days. NCT04355936 (Completed). Findings A pragmatic decision to end the study before the third interim analysis was made on Oct. 30th due to sharp reduction in recruitment. A total of 162 patients were randomized. 158 patients enrolled between May 14 and October 30 2020, were included in the analysis, 80 in the standard care and 78 in the telmisartan added to standard care group. Baseline absolute CRP serum levels were 5.53 ± 6.19 mg/dL (95% CI 6.91 to 4.15, n = 80) and 9.04 ± 7.69 (95% CI 9.04 to 10.82, n = 74) in the standard care and telmisartan added to standard care groups, respectively. Day 5 control-group CRP levels were 6.06 ± 6.95 mg/dL (95% CI 7.79-4.35, n = 66) while telmisartan group were 3.83 ± 5.08 mg/dL (95% CI 5.08-2.59, n = 66, p = 0.038). Day 8 CRP levels were 6.30 ± 8.19 mg/dL (95% CI 8.79-3.81, n = 44) and 2.37 ± 3.47 mg/dL (95% CI 3.44-1.30, n = 43, p = 0.0098) in the control and telmisartan groups, respectively (all values expressed as mean ± SD). Kaplan-Meier analysis showed that telmisartan-treated patients had a lower median time-to-discharge (control=15 days; telmisartan=9 days). Death by day 30 was reduced in the telmisartan-treated group (control 22.54%, 16/71; telmisartan 4.29%, 3/70 participants; p = 0.0023). Composite ICU, mechanical ventilation or death was reduced by telmisartan treatment at days 15 and 30. No adverse events were reported. Interpretation Our study suggests that the ARB telmisartan, a widely used antihypertensive drug, is safe and could reduce morbidity and mortality in hospitalized patients infected with SARS -CoV-2 by anti-inflammatory effects. Further studies employing telmisartan are needed for confirmation of our results and to define its true therapeutic value as a tool against Covid-19.
Collapse
Affiliation(s)
- Mariano Duarte
- Laboratorio de Hipertensión, División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
- Segunda Cátedra de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Facundo Pelorosso
- Asociación Argentina de Medicamentos, Ciudad Autónoma de Buenos Aires, Argentina
- Servicio de Anatomía Patológica, Hospital de Alta Complejidad El Calafate SAMIC, Argentina
| | | | - M. Victoria Salgado
- Centro de Estudios de Estado y Sociedad, Ciudad Autónoma de Buenos Aires, Argentina
- Servicio de Medicina Familiar, Hospital de Alta Complejidad El Calafate SAMIC, Argentina
| | - Héctor Vetulli
- Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos, Sanatorio Otamendi y Miroli, Ciudad Autónoma de Buenos Aires, Argentina
| | - Analía Aquieri
- Laboratorio de Hipertensión, División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Francisco Azzato
- Departamento de Medicina, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Marcela Castro
- Laboratorio de Terapia Intensiva y Urgencias, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Javier Coyle
- División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Ignacio Davolos
- División de Cardiología, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Ignacio Fernandez Criado
- Sección de Tecnología Educativa e Informática Médica, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Rosana Gregori
- Servicio de Guardia, Hospital Español de Buenos Aires, Argentina
| | | | - María C. Rubio
- División de Cardiología, Hospital Español de Buenos Aires, Argentina
| | - Sergio Sarquis
- Unidad de Cuidados Intensivos, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - Fernando Wahlmann
- Departamento de Medicina Interna, Hospital Español de Buenos Aires, Argentina
| | - Rodolfo P. Rothlin
- Asociación Argentina de Medicamentos, Ciudad Autónoma de Buenos Aires, Argentina
- Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Argentina
| |
Collapse
|
4
|
Rothlin RP, Duarte M, Pelorosso FG, Nicolosi L, Salgado MV, Vetulli HM, Spitzer E. Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials. Front Pharmacol 2021; 12:603736. [PMID: 33854432 PMCID: PMC8039444 DOI: 10.3389/fphar.2021.603736] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 02/02/2021] [Indexed: 12/12/2022] Open
Abstract
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotensin II-driven lung inflammation. This has triggered several prospective clinical trials. In this commentary we provide an overview and analysis of current ongoing clinical trials aimed at evaluating the therapeutic efficacy of angiotensin receptor blocker (ARB) use in COVID-19. The relevance of the results of these trials will have to be interpreted depending on the stage and severity of the disease and in light of the start time of their prescription related to the time of diagnosis of COVID-19 as well as the administered doses.
Collapse
Affiliation(s)
- Rodolfo Pedro Rothlin
- Sociedad Argentina de Farmacología Clínica, Asociación Médica Argentina, Buenos Aires, Argentina
| | - Mariano Duarte
- Hospital de Clínicas ‘José de San Martín’, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | | | | | - M. Victoria Salgado
- Hospital de Alta Complejidad El Calafate SAMIC, El Calafate, Provincia de Santa Cruz, Argentina
- Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina
| | - Héctor Miguel Vetulli
- Servicio de Electrofisiología Cardíaca, Arritmias y Marcapasos. Sanatorio Otamendi y Miroli, Buenos Aires, Argentina
| | | |
Collapse
|
5
|
Salgado MV, Penko J, Fernandez A, Konfino J, Coxson PG, Bibbins-Domingo K, Mejia R. Projected impact of a reduction in sugar-sweetened beverage consumption on diabetes and cardiovascular disease in Argentina: A modeling study. PLoS Med 2020; 17:e1003224. [PMID: 32722677 PMCID: PMC7386620 DOI: 10.1371/journal.pmed.1003224] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 06/22/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Sugar-sweetened beverage (SSB) consumption is associated with obesity, diabetes, and hypertension. Argentina is one of the major consumers of SSBs per capita worldwide. Determining the impact of SSB reduction on health will inform policy debates. METHODS AND FINDINGS We used the Cardiovascular Disease Policy Model-Argentina (CVD Policy Model-Argentina), a local adaptation of a well-established computer simulation model that projects cardiovascular and mortality events for the population 35-94 years old, to estimate the impact of reducing SSB consumption on diabetes incidence, cardiovascular events, and mortality in Argentina during the period 2015-2024, using local demographic and consumption data. Given uncertainty regarding the exact amount of SSBs consumed by different age groups, we modeled 2 estimates of baseline consumption (low and high) under 2 different scenarios: a 10% and a 20% decrease in SSB consumption. We also included a range of caloric compensation in the model (0%, 39%, and 100%). We used Monte Carlo simulations to generate 95% uncertainty intervals (UIs) around our primary outcome measures for each intervention scenario. Over the 2015-2024 period, a 10% reduction in SSBs with a caloric compensation of 39% is projected to reduce incident diabetes cases by 13,300 (95% UI 10,800-15,600 [low SSB consumption estimate]) to 27,700 cases (95% UI 22,400-32,400 [high SSB consumption estimate]), i.e., 1.7% and 3.6% fewer cases, respectively, compared to a scenario of no change in SSB consumption. It would also reduce myocardial infarctions by 2,500 (95% UI 2,200-2,800) to 5,100 (95% UI 4,500-5,700) events and all-cause deaths by 2,700 (95% UI 2,200-3,200) to 5,600 (95% UI 4,600-6,600) for "low" and "high" estimates of SSB intake, respectively. A 20% reduction in SSB consumption with 39% caloric compensation is projected to result in 26,200 (95% UI 21,200-30,600) to 53,800 (95% UI 43,900-62,700) fewer cases of diabetes, 4,800 (95% UI 4,200-5,300) to 10,000 (95% UI 8,800-11,200) fewer myocardial infarctions, and 5,200 (95% UI 4,300-6,200) to 11,000 (95% UI 9,100-13,100) fewer deaths. The largest reductions in diabetes and cardiovascular events were observed in the youngest age group modeled (35-44 years) for both men and women; additionally, more events could be avoided in men compared to women in all age groups. The main limitations of our study are the limited availability of SSB consumption data in Argentina and the fact that we were only able to model the possible benefits of the interventions for the population older than 34 years. CONCLUSIONS Our study finds that, even under conservative assumptions, a relatively small reduction in SSB consumption could lead to a substantial decrease in diabetes incidence, cardiovascular events, and mortality in Argentina.
Collapse
Affiliation(s)
- M. Victoria Salgado
- Centro de Estudios de Estado y Sociedad (CEDES), Ciudad de Buenos Aires, Argentina
- * E-mail:
| | - Joanne Penko
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, United States of America
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
| | - Alicia Fernandez
- Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
| | - Jonatan Konfino
- Centro de Estudios de Estado y Sociedad (CEDES), Ciudad de Buenos Aires, Argentina
| | - Pamela G. Coxson
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, United States of America
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
| | - Kirsten Bibbins-Domingo
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, United States of America
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
- Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
| | - Raul Mejia
- Centro de Estudios de Estado y Sociedad (CEDES), Ciudad de Buenos Aires, Argentina
| |
Collapse
|
6
|
Salgado MV, O'Flaherty M, Mejía R. The role of computer simulation models in the design of public policies. Medicina (B Aires) 2020; 80:681-684. [PMID: 33254113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023] Open
Abstract
Cardiovascular diseases are the number one cause of death globally, but their optimal prevention remains a challenge. A high-risk approach can only have a limited effect at a population level, while population-based strategies can improve and extend the coverage of a high-risk approach. However, one main problem for promoting cardiovascular diseases prevention public policies is the difficulty to foresee population health benefits of a single policy. Computer simulation models can assist with this problem, due to their ability to estimate intervention effects over different periods, and by scaling up the evidence to a broader, more diverse population. Their applicability to countries with different social, political and economic contexts can assist in the design of public policies. There are several models that assess health and economics scenarios, but regardless which model is chosen, when adequately used, they can provide reasonable estimations of health policies' impact. There is a growing consensus amongst the public health communities about the powerful role of population-level policies. They are more effective, cost saving and more equitable when compared with individual-level interventions. Policy makers and the public health community need to make further progress in changing the focus of prevention, from individuals to populations.
Collapse
Affiliation(s)
- M Victoria Salgado
- Centro de Estudios de Estado y Sociedad (CEDES), Buenos Aires, Argentina. E-mail:
| | | | - Raúl Mejía
- Centro de Estudios de Estado y Sociedad (CEDES), Buenos Aires, Argentina
- Hospital de Clínicas José de San Martin, Universidad de Buenos Aires, Argentina
| |
Collapse
|
7
|
Salgado MV, Coxson P, Konfino J, Penko J, Irazola VE, Gutiérrez L, Fernández A, Mejía R. Update of the cardiovascular disease policy model to predict cardiovascular events in Argentina. Medicina (B Aires) 2019; 79:438-444. [PMID: 31829945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023] Open
Abstract
Cardiovascular disease (CVD) is the leading cause of death in Argentina. Computer simulation models allow to extrapolate evidence to broader populations than the originally studied, over longer timeframes, and to compare different subpopulations. The Cardiovascular Disease Policy Model (CVDPM) is a computer simulation state transition model used to represent and project future CVD mortality and morbidity in the population 35 years-old and older. The objective of this study was to update Argentina's version of the CVDPM. For this purpose, information from the 2010 National Census, the 2013 National Risk Factor Survey, CESCAS I study, and PrEViSTA study were used to update the dynamics of population size, demographics, and CVD risk factor distributions over time. Model projections were later calibrated by comparing them to actual data on CVD events and mortality in the year 2010 (baseline year) in Argentina. Country statistics for people 35 years-old and older reported for 2010 a total of 41 219 myocardial infarctions (MIs), 58 658 strokes, and 281 710 total deaths. The CVDPM, in turn, predicted 41 265 MIs (difference: 0.11%), 58 584 strokes (difference: 0.13%), and 280 707 total deaths (difference: 0.36%) in the same population. In all cases, the final version of the model predicted the actual number of events with an accuracy superior to 99.5%, and could be used to forecast the changes in CVD incidence and mortality after the implementation of public policies.
Collapse
Affiliation(s)
- M Victoria Salgado
- Centro de Estudios de Estado y Sociedad (CEDES), Buenos Aires, Argentina. E-mail:
| | - Pam Coxson
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, USA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
| | - Jonatan Konfino
- Centro de Estudios de Estado y Sociedad (CEDES), Buenos Aires, Argentina
| | - Joanne Penko
- Center for Vulnerable Populations, University of California San Francisco, San Francisco, California, USA
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
| | - Vilma E Irazola
- Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
- Centro de Excelencia en Salud Cardiovascular para América del Sur (CESCAS), Buenos Aires, Argentina
| | - Laura Gutiérrez
- Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina
- Centro de Excelencia en Salud Cardiovascular para América del Sur (CESCAS), Buenos Aires, Argentina
| | - Alicia Fernández
- Department of Medicine, University of California San Francisco, San Francisco, California, USA
| | - Raúl Mejía
- Centro de Estudios de Estado y Sociedad (CEDES), Buenos Aires, Argentina
| |
Collapse
|
8
|
Salgado MV, Mejia R, Kaplan CP, Perez-Stable EJ. Smoking behavior and use of tobacco industry sponsored websites among medical students and young physicians in Argentina. J Med Internet Res 2014; 16:e35. [PMID: 24509433 PMCID: PMC3936273 DOI: 10.2196/jmir.2528] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Revised: 05/28/2013] [Accepted: 10/30/2013] [Indexed: 11/28/2022] Open
Abstract
Background Internet-based marketing has become an attractive option for promoting tobacco products due to its potential to avoid advertising restrictions. In Argentina, several cigarette brands have designed websites for the local market, which promote user participation. Objective The intent of the study was to report on the use of tobacco company-sponsored websites by medical students and recently graduated physicians. Methods An online self-administered survey was conducted among eligible medical students and recent graduates from the University of Buenos Aires (UBA). Sampling was from lists of email addresses of students enrolled in two required courses. Eligibility criteria were ages 18-30 years and reporting on smoking status. Questions on Internet use included accessing a tobacco brand website at least once during their lifetime and any use of tobacco promotional materials. Results The response rate was 35.08% (1743/4969). The final sample included 1659 participants: 73.06% (1212/1659) were women and mean age was 26.6 years (SD 1.9). The majority were current medical students (55.70%, 924/1659) and 27.31% (453/1659) were current smokers. Men were more likely to report having seen a tobacco advertisement on the Internet (P=.001), to have received a tobacco promotion personally addressed to them (P=.03), to have used that promotion (P=.02), and to have accessed a tobacco-sponsored website (P=.01). Among respondents, 19.35% (321/1659) reported having accessed a tobacco-sponsored website at least once in their lifetime and almost all of them (93.8%, 301/321) accessed these sites only when it was necessary for participating in a marketing promotion. Most people logging on for promotions reported entering once a month or less (58.9%, 189/321), while 25.5% (82/321) reported accessing the tobacco industry Internet sites once a week or more. In adjusted logistic regression models, participants were more likely to have accessed a tobacco brand website if they were former smokers (OR 2.45, 95% CI 1.42-4.22) or current (OR 8.12, 95% CI 4.66-14.16), if they reported having seen a tobacco advertisement on the Internet (OR 2.44, 95% CI 1.77-3.37), received a tobacco promotion personally addressed to them (OR 5.62; 95% CI 4.19-7.55), or used one of these promotions (OR 14.05, 95% CI 9.21-21.43). Respondents were more likely to be current smokers if they received a tobacco promotion (OR 2.64, 95% CI 2.02-3.45) or if they used one of these promotions (OR 1.93, 95% CI 1.31-2.85). Conclusions Our study suggests that tobacco industry websites reach medical students and young physicians in a middle-income country with their marketing promotions. Current or proposed legislation to ban tobacco advertising needs to include Internet sites and related social media.
Collapse
|
9
|
Salgado MV, Pérez-Stable EJ, Primack BA, Kaplan CP, Mejia RM, Gregorich SE, Alderete E. Association of media literacy with cigarette smoking among youth in Jujuy, Argentina. Nicotine Tob Res 2011; 14:516-21. [PMID: 22193569 DOI: 10.1093/ntr/ntr240] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
INTRODUCTION Latin America has the highest prevalence of tobacco use by youth. Higher media literacy, defined as the ability to analyze and evaluate media messages, has been associated with lower smoking among youth in the United States. The objective of this study was to determine whether media literacy related to smoking is independently associated with current smoking and susceptibility to future smoking in a sample of mostly indigenous youth in Jujuy, Argentina. METHODS In 2006, a self-administered survey was conducted among 10th grade students sampled from 27 randomly selected urban and rural schools in Jujuy. Survey items measured smoking behavior (ever, never, and current), susceptibility to future smoking among never-smokers (definitely not accept a cigarette from a friend or to smoke in the future), 5 items assessing smoking media literacy (SML), and risk factors for smoking. RESULTS Of the 3,470 respondents, 1,170 (34%) reported having smoked in the previous 30 days (current). Of the 1,430 students who had never smoked, 912 (64%) were susceptible to future smoking. High media literacy was present in 38%. Using multiple logistic regression, fully adjusted models showed that high media literacy was significantly associated as a protective factor of being a current smoker (odds ratio [OR] = 0.81; 95% CI = 0.67-0.97) and of being susceptible to future smoking (OR = 0.73; 95% CI = 0.58-0.92) among those who had never smoked. CONCLUSIONS Among youth in Jujuy, higher SML was significantly associated with both lower current smoking and susceptibility to future smoking. Teaching SML may be a valuable component in a prevention intervention in this population.
Collapse
Affiliation(s)
- M Victoria Salgado
- Division of General Internal Medicine, Medical Effectiveness Research Center for Diverse Populations, Department of Medicine, University of California San Francisco, San Francisco, CA 94143-0856, USA
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
OBJECTIVE Menthol is an important additive in most tobacco products and is an identifying characteristic of many brands. We assessed tobacco companies' research on direct disease-inducing effects of menthol and menthol cigarettes. METHODS A search was conducted among documents included in the Legacy Tobacco Documents Library. Relevant documents addressed subject areas such as pharmacology, short-term and long-term effects and biomarkers of smoking exposure. RESULTS The documents contain little internal industry research on the disease-inducing effects of menthol. Most information in the tobacco industry documents are reviews of the published biomedical literature, from which the companies concluded that menthol did not have any direct disease-inducing effects. Evidence that contradicted this conclusion was downplayed. Except for one study, there was no evidence of the companies following up on positive findings in the literature with their own studies. In one case, results were presented at a public scientific meeting concluding that 'There were no effects from addition of menthol to test or reference cigarettes', when a company's internal pathology analysis contradicted this statement. CONCLUSION The available industry documents suggest that tobacco companies conducted little research on the potential disease-inducing effects of menthol and did not pursue studies that suggested adverse effects.
Collapse
Affiliation(s)
- M Victoria Salgado
- Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, California, USA
| | - Stanton A Glantz
- Division of Cardiology, Department of Medicine, and Center for Tobacco Control Research and Education, University of California, San Francisco, California, USA
| |
Collapse
|
11
|
Fernandez A, Schillinger D, Warton EM, Adler N, Moffet HH, Schenker Y, Salgado MV, Ahmed A, Karter AJ. Language barriers, physician-patient language concordance, and glycemic control among insured Latinos with diabetes: the Diabetes Study of Northern California (DISTANCE). J Gen Intern Med 2011; 26:170-6. [PMID: 20878497 PMCID: PMC3019330 DOI: 10.1007/s11606-010-1507-6] [Citation(s) in RCA: 208] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2010] [Revised: 08/02/2010] [Accepted: 08/06/2010] [Indexed: 11/29/2022]
Abstract
BACKGROUND A significant proportion of US Latinos with diabetes have limited English proficiency (LEP). Whether language barriers in health care contribute to poor glycemic control is unknown. OBJECTIVE To assess the association between limited English proficiency (LEP) and glycemic control and whether this association is modified by having a language-concordant physician. DESIGN Cross-sectional, observational study using data from the 2005-2006 Diabetes Study of Northern California (DISTANCE). Patients received care in a managed care setting with interpreter services and self-reported their English language ability and the Spanish language ability of their physician. Outcome was poor glycemic control (glycosylated hemoglobin A1c > 9%). KEY RESULTS The unadjusted percentage of patients with poor glycemic control was similar among Latino patients with LEP (n = 510) and Latino English-speakers (n = 2,683), and higher in both groups than in whites (n = 3,545) (21% vs 18% vs. 10%, p < 0.005). This relationship differed significantly by patient-provider language concordance (p < 0.01 for interaction). LEP patients with language-discordant physicians (n = 115) were more likely than LEP patients with language-concordant physicians (n = 137) to have poor glycemic control (27.8% vs 16.1% p = 0.02). After controlling for potential demographic and clinical confounders, LEP Latinos with language-concordant physicians had similar odds of poor glycemic control as Latino English speakers (OR 0.89; CI 0.53-1.49), whereas LEP Latinos with language-discordant physicians had greater odds of poor control than Latino English speakers (OR 1.76; CI 1.04-2.97). Among LEP Latinos, having a language discordant physician was associated with significantly poorer glycemic control (OR 1.98; CI 1.03-3.80). CONCLUSIONS Language barriers contribute to health disparities among Latinos with diabetes. Limited English proficiency is an independent predictor for poor glycemic control among insured US Latinos with diabetes, an association not observed when care is provided by language-concordant physicians. Future research should determine if strategies to increase language-concordant care improve glycemic control among US Latinos with LEP.
Collapse
Affiliation(s)
- Alicia Fernandez
- Department of Medicine, University of California, San Francisco, CA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|